Milan J. Anadkat MDProfessor and Director, Clinical Trials, Division of Dermatology, Washington University School of Medicine St. Louis, Missouri
Dr. Milan Anadkat is a Professor of Dermatology at Washington University School of Medicine. He is currently the Director of Clinical Trials for the Division of Dermatology. He is also Chair of the Office of Faculty Development for the Department of Internal Medicine. He recently stepped down from the position of Dermatology Residency Program Director.
His clinical focus is in the area of complex medical dermatology, with a focused interest in oncodermatology. He has published widely on topics such as dermatologic therapeutics, graft-versus-host disease, and chemotherapy-induced adverse reactions. He has delivered nearly 100 invited lectures on these topics locally, regionally, nationally, and internationally.
Dr. Anadkat is a member of the American Academy of Dermatology, Medical Dermatology Society, American Professors of Dermatology, Society of Investigative Dermatology, and Multinational Association of Supportive Care in Cancer.
Dr. Anadkat is currently the Deputy Editor for the Journal of the American Academy of Dermatology Case Reports. He is former (founding) Editor-in-Chief for the AAD Online Resident Question Bank. He is currently on the Board of Directors for the Medical Dermatology Socieity, Association for Professors in Dermatology, and Missouri State Dermatologic Society.
Recent Contributions to PracticeUpdate:
- Cutaneous and Noncutaneous Immune-Related AEs Among Patients With Advanced Cancer
- Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With EGFR Inhibitors at a Cancer Center
- Dermatology Consultation Reduces Interruption of Oncologic Management Among Hospitalized Patients With Immune-Related Adverse Events
- Targeted Anticancer Agents May Cause Skin and Hair Pigmentary Changes
- Hair Repigmentation During Anti–PD-1 and Anti–PD-L1 Immunotherapy for Lung Cancer
- Methotrexate-Induced Epidermal Necrosis: A Case Series of 24 Patients
- Efficacy and Safety of Guselkumab vs Adalimumab for Continuous Treatment of Moderate to Severe Psoriasis
- Recognize the Range of Skin Reactions to EGFR Inhibitors
- Methotrexate in the Treatment of Pemphigus Vulgaris: Experience in 23 Patients